1. Succinylcholine produces neuromuscular blockade by a mechanism that is fundamentally different from the non-depolarizing agents. Which of the following best describes how succinylcholine blocks neuromuscular transmission?
A) It competitively occupies the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction without activating it, preventing acetylcholine from binding and triggering depolarization.
B) It binds to and activates the nicotinic acetylcholine receptor at the neuromuscular junction, producing an initial depolarization (visible as fasciculations) followed by a sustained depolarized state that renders the end plate unresponsive to further acetylcholine stimulation.
C) It inhibits acetylcholinesterase at the neuromuscular junction, causing acetylcholine to accumulate and produce prolonged receptor stimulation that eventually desensitizes the end plate.
D) It blocks voltage-gated sodium channels in the muscle fiber membrane, preventing propagation of the action potential beyond the neuromuscular junction regardless of receptor activation status.
E) It depletes acetylcholine stores from the presynaptic terminal by inhibiting choline acetyltransferase, reducing the amount of neurotransmitter available to activate postsynaptic receptors.
ANSWER: B
Rationale:
This question asked you to identify the unique mechanism by which succinylcholine produces neuromuscular block. Succinylcholine is a depolarizing neuromuscular blocking agent — it binds to and activates the nAChR just as acetylcholine does, opening the ion channel and producing initial end-plate depolarization that manifests clinically as the visible muscle fasciculations seen after injection. Because succinylcholine is resistant to hydrolysis by acetylcholinesterase (it is hydrolyzed instead by plasma pseudocholinesterase at a much slower rate), it remains bound to the receptor for 8 to 12 minutes under normal enzyme activity, sustaining end-plate depolarization. This persistent depolarized state inactivates the perijunctional sodium channels required for action potential propagation, rendering the muscle unresponsive to further stimulation — a state called Phase I (depolarizing) block.
Option A: Option A is incorrect because that description — competitive binding without receptor activation — defines the mechanism of non-depolarizing agents such as rocuronium and vecuronium, not succinylcholine.
Option C: Option C is incorrect because succinylcholine does not inhibit acetylcholinesterase; acetylcholinesterase inhibitors such as neostigmine actually antagonize non-depolarizing block.
Option D: Option D is incorrect because succinylcholine does not act on voltage-gated sodium channels; its action is entirely at the nAChR.
Option E: Option E is incorrect because succinylcholine does not affect acetylcholine synthesis or presynaptic release; its site of action is exclusively postsynaptic at the nicotinic receptor.
2. A 38-year-old woman with a full stomach requires emergency tracheal intubation. The anesthesiologist selects succinylcholine for rapid sequence intubation (RSI) — a technique that prioritizes the fastest possible onset of neuromuscular block to minimize the window of aspiration risk. What is the standard intravenous dose of succinylcholine for RSI in an adult?
A) 0.1 mg/kg intravenously, which produces complete neuromuscular block within 30 seconds and a clinical duration of 3 to 5 minutes.
B) 0.5 mg/kg intravenously, which balances rapid onset with a shorter duration than full intubating doses, reducing the risk of prolonged block if intubation fails.
C) 2.5 mg/kg intravenously, which ensures the fastest possible onset by saturating all available nicotinic receptors at the neuromuscular junction simultaneously.
D) 1.0 to 1.5 mg/kg intravenously, which produces intubating conditions within 45 to 60 seconds at the larynx with a clinical duration of 8 to 12 minutes under normal pseudocholinesterase activity.
E) 0.3 mg/kg intravenously, which is the minimum dose required to produce complete block while limiting the cardiovascular side effects associated with higher doses.
ANSWER: D
Rationale:
This question asked you to recall the standard adult intravenous dose of succinylcholine for rapid sequence intubation. The accepted RSI dose is 1.0 to 1.5 mg/kg intravenously; this dose reliably produces intubating conditions at the larynx within 45 to 60 seconds and a clinical duration of 8 to 12 minutes under normal plasma pseudocholinesterase activity, providing the brief window of paralysis needed for RSI with rapid spontaneous recovery if intubation fails. In infants and young children, a higher dose of 1.5 to 2.0 mg/kg is used because of the proportionally larger volume of distribution in pediatric patients.
Option A: Option A is incorrect because 0.1 mg/kg is a sub-intubating dose — too small to produce reliable complete block for RSI; a small non-depolarizing dose of this magnitude is sometimes used as a defasciculating pretreatment but is not an intubating dose.
Option B: Option B is incorrect because 0.5 mg/kg is below the standard RSI dose range and would not consistently produce the rapid complete block required for safe RSI in a full-stomach patient.
Option C: Option C is incorrect because 2.5 mg/kg substantially exceeds the standard dose; no clinical benefit over 1.5 mg/kg has been demonstrated and higher doses only prolong duration and increase adverse effects.
Option E: Option E is incorrect because 0.3 mg/kg is a sub-therapeutic dose for RSI and has no established role as a standard intubating regimen.
3. Succinylcholine normally raises serum potassium by only about 0.5 mEq/L — a clinically trivial increase. However, in certain pathological states, the same dose can raise serum potassium by 5 to 10 mEq/L or more, causing life-threatening arrhythmias. What is the underlying mechanism responsible for this dangerous potassium surge in vulnerable patients?
A) Pathological upregulation of extrajunctional fetal-type nicotinic acetylcholine receptors across the entire muscle surface causes the succinylcholine-induced depolarization to extend far beyond the normal end-plate zone, releasing massive amounts of intracellular potassium through millions of additional ion channels simultaneously.
B) Succinylcholine directly inhibits the sodium-potassium ATPase pump in skeletal muscle, preventing potassium reuptake after depolarization and causing progressive extracellular potassium accumulation with each successive dose.
C) The pathological states listed increase circulating aldosterone levels, which sensitizes skeletal muscle nicotinic receptors to succinylcholine and amplifies potassium efflux per receptor activation event.
D) Muscle fiber necrosis in the pathological states releases large quantities of intracellular potassium into the circulation independently of succinylcholine, and the drug acts as a trigger that accelerates this necrotic process.
E) Pseudocholinesterase deficiency in these pathological states prolongs succinylcholine exposure at the end plate, causing repeated cycles of depolarization and repolarization that cumulatively release more potassium than a single brief depolarization event.
ANSWER: A
Rationale:
This question asked you to identify the mechanism behind succinylcholine-induced life-threatening hyperkalemia in vulnerable patients. In normal subjects, nAChRs are confined almost exclusively to the junctional end plate; succinylcholine depolarizes only this small zone, releasing a trivial amount of potassium. In pathological states characterized by denervation (stroke, spinal cord injury, peripheral neuropathy), prolonged immobilization, severe burns after 24 hours, or prolonged critical illness, the muscle upregulates extrajunctional fetal-type nAChRs across the entire sarcolemmal surface. When succinylcholine is administered, it activates all of these receptors simultaneously, and the massive depolarization of the entire muscle membrane releases potassium from millions of additional channels — producing a serum potassium rise of 5 to 10 mEq/L or more that can precipitate ventricular fibrillation and cardiac arrest.
Option B: Option B is incorrect because succinylcholine does not inhibit the sodium-potassium ATPase; its action is restricted to nicotinic receptor activation.
Option C: Option C is incorrect because aldosterone acts on renal mineralocorticoid receptors to regulate sodium and potassium balance — it does not sensitize skeletal muscle nicotinic receptors or amplify potassium efflux per receptor event.
Option D: Option D is incorrect because the potassium release is a direct consequence of succinylcholine-induced depolarization through upregulated channels, not muscle fiber necrosis; the drug does not accelerate necrotic processes.
Option E: Option E is incorrect because while pseudocholinesterase deficiency prolongs succinylcholine block, it is not the mechanism responsible for hyperkalemia; the key variable is the number of extrajunctional receptors present, not the duration of drug exposure.
4. A 45-year-old man sustains major burns covering 40% of his body surface area. The burn team asks about succinylcholine use at various points during his care. At which of the following time points does succinylcholine pose the highest risk of life-threatening hyperkalemia?
A) Within the first hour after the burn injury, because the massive tissue destruction immediately releases large amounts of intracellular potassium into the systemic circulation before the muscle has time to compensate.
B) During the resuscitation phase in the first 6 to 12 hours after injury, because aggressive fluid administration dilutes serum potassium and sensitizes muscle receptors to depolarizing agents.
C) Beginning approximately 24 hours after the burn injury and persisting for up to one year, because extrajunctional nicotinic acetylcholine receptors upregulate progressively over days after the injury and remain elevated throughout the healing period.
D) Only during the acute inflammatory phase (days 3 to 7), after which receptor upregulation resolves as the inflammatory mediators responsible for extrajunctional receptor expression are cleared.
E) The risk is constant from the moment of injury regardless of timing, because burned muscle tissue maintains a permanent high-density extrajunctional receptor expression that never returns to baseline.
ANSWER: C
Rationale:
This question asked you to identify the time window of hyperkalemia risk from succinylcholine in burn patients. The key principle is that succinylcholine-associated hyperkalemia in burns is not immediate — extrajunctional nAChR upregulation requires time to develop after the injury. The risk begins at approximately 24 hours after the burn and persists for up to one year, reflecting the prolonged upregulation of extrajunctional receptors that accompanies the denervation-like state produced by severe thermal injury. A patient with an acute burn who receives succinylcholine within the first few hours of injury is not at substantially elevated hyperkalemia risk from this mechanism, but the same patient after 24 to 48 hours carries a high risk. This time course is clinically critical because burn patients often require multiple procedures over many months.
Option A: Option A is incorrect because the mechanism is not immediate release of pre-existing intracellular potassium from destroyed tissue — the danger is succinylcholine-triggered channel opening through upregulated extrajunctional receptors, which requires time to develop.
Option B: Option B is incorrect because the hyperkalemia risk is not driven by fluid resuscitation or dilutional effects sensitizing receptors — it is driven by receptor upregulation that has not yet occurred in the first 6 to 12 hours.
Option D: Option D is incorrect because the risk does not resolve after the acute inflammatory phase; extrajunctional receptor upregulation in burns is prolonged and can persist for many months beyond the acute period.
Option E: Option E is incorrect because the risk is not present from the moment of injury — the upregulation requires approximately 24 hours to develop, so succinylcholine is generally acceptable for emergency airway management immediately after acute burn injury.
5. A 22-year-old man receives succinylcholine for emergency intubation. Within minutes he develops rapidly rising end-tidal CO2, muscle rigidity, hyperthermia with temperature rising 1°C every 5 minutes, and metabolic acidosis — a presentation consistent with malignant hyperthermia (MH). What is the primary molecular mechanism underlying this life-threatening crisis?
A) Succinylcholine activates complement cascade proteins in genetically susceptible individuals, triggering systemic inflammatory cytokine release that drives the hypermetabolic state and hyperthermia independently of skeletal muscle calcium handling.
B) Succinylcholine inhibits mitochondrial oxidative phosphorylation in skeletal muscle cells, causing anaerobic metabolism, heat generation, and lactic acidosis in individuals with specific mitochondrial DNA mutations.
C) Succinylcholine activates the sympathetic nervous system in MH-susceptible patients, causing massive catecholamine release that drives skeletal muscle hypermetabolism, tachycardia, and hyperthermia through beta-adrenergic receptor stimulation.
D) Succinylcholine crosses the sarcoplasmic reticulum membrane and directly alkylates the calcium ATPase pump (SERCA), preventing calcium reuptake and causing intracellular calcium accumulation that activates muscle contraction and heat generation.
E) In individuals carrying mutations in the ryanodine receptor gene (RYR1) — the calcium release channel of the sarcoplasmic reticulum — succinylcholine triggers uncontrolled calcium efflux from the sarcoplasmic reticulum into the muscle cell cytoplasm, causing sustained muscle contraction, rapid oxygen consumption, and the hypermetabolic crisis.
ANSWER: E
Rationale:
This question asked you to identify the molecular mechanism of malignant hyperthermia triggered by succinylcholine. MH is a pharmacogenetic disorder most commonly caused by autosomal dominant mutations in the ryanodine receptor gene (RYR1), which encodes the calcium release channel of the sarcoplasmic reticulum — the intracellular organelle that stores calcium in muscle cells. In susceptible individuals, succinylcholine (as well as volatile anesthetic agents) triggers the abnormal ryanodine receptor to release calcium in an uncontrolled and self-sustaining fashion. The resulting massive cytoplasmic calcium accumulation drives sustained muscle contraction, rapidly exhausts ATP stores, generates intense heat (temperature can rise 1°C every 5 minutes), and produces the constellation of hypercarbia, acidosis, rhabdomyolysis, and hyperkalemia that characterizes the full MH crisis. Without treatment, the condition is rapidly fatal.
Option A: Option A is incorrect because MH is a primary skeletal muscle calcium-handling disorder, not an immune or complement-mediated event.
Option B: Option B is incorrect because MH is caused by ryanodine receptor-mediated calcium release, not by mitochondrial DNA mutations affecting oxidative phosphorylation.
Option C: Option C is incorrect because succinylcholine does not trigger catecholamine release in MH; the crisis is a direct consequence of uncontrolled intramuscular calcium dysregulation, not sympathetic activation.
Option D: Option D is incorrect because succinylcholine does not directly act on the SERCA pump; the primary defect is in the ryanodine receptor calcium release channel, not in calcium reuptake.
6. The patient in the previous scenario is confirmed to be in a malignant hyperthermia (MH) crisis. The anesthesia team initiates emergency treatment. Which of the following is the specific pharmacological antidote for MH, and what is its mechanism of action?
A) Neostigmine — an acetylcholinesterase inhibitor that reverses the succinylcholine-triggered depolarization at the neuromuscular junction by increasing acetylcholine concentration and competitively displacing succinylcholine from nicotinic receptors.
B) Dantrolene — a ryanodine receptor antagonist that inhibits calcium release from the sarcoplasmic reticulum, directly interrupting the uncontrolled calcium efflux that drives the hypermetabolic crisis; initial dose is 2.5 mg/kg intravenously, repeated every 5 minutes as needed.
C) Sugammadex — a modified cyclodextrin that encapsulates succinylcholine molecules in the plasma, rapidly reducing the concentration of free drug available to maintain the ryanodine receptor in its abnormally activated state.
D) Calcium gluconate — administered intravenously to competitively inhibit the excess intracellular calcium by saturating cytoplasmic calcium-binding proteins, thereby reducing the sustained muscle contraction driving the hypermetabolic state.
E) Sodium bicarbonate — the primary intervention for MH because correction of the metabolic acidosis reverses the allosteric conformational change in the ryanodine receptor that sustains pathological calcium release.
ANSWER: B
Rationale:
This question asked you to identify the specific antidote for malignant hyperthermia and its mechanism. Dantrolene is the only pharmacological agent with direct activity against the MH crisis. It acts as a ryanodine receptor antagonist — it binds to the ryanodine receptor 1 (RYR1) and inhibits calcium release from the sarcoplasmic reticulum, directly interrupting the pathological calcium efflux that drives sustained muscle contraction, hypermetabolism, and hyperthermia. The initial intravenous dose is 2.5 mg/kg, repeated every 5 minutes until the crisis is controlled; total doses may exceed 10 mg/kg. Dantrolene must be immediately available in any facility that uses succinylcholine or volatile anesthetic agents — delayed access is a major cause of MH mortality.
Option A: Option A is incorrect because neostigmine acts at the neuromuscular junction to increase acetylcholine availability for reversing non-depolarizing block; it has no mechanism of action relevant to ryanodine receptor-mediated calcium dysregulation and would be harmful if given in MH.
Option C: Option C is incorrect because sugammadex encapsulates aminosteroid non-depolarizing agents such as rocuronium and vecuronium — it has no binding affinity for succinylcholine and no mechanism to reverse the ryanodine receptor pathology driving MH.
Option D: Option D is incorrect because administering additional calcium would worsen the intracellular calcium overload driving the crisis; calcium gluconate is indicated for hyperkalemia management but not for the MH mechanism itself.
Option E: Option E is incorrect because sodium bicarbonate may be used as supportive therapy to treat the metabolic acidosis that develops during MH, but it does not address the underlying ryanodine receptor pathology and is not the primary or specific treatment.
7. A patient who received succinylcholine during an elective procedure remains apneic and paralyzed 2 hours after the drug was administered — a duration far exceeding the expected 8 to 12 minutes. Pseudocholinesterase (plasma butyrylcholinesterase) deficiency is suspected. A dibucaine number is obtained to characterize the enzyme variant. The dibucaine number measures the percentage inhibition of pseudocholinesterase by the local anesthetic dibucaine. Which of the following correctly describes the dibucaine number interpretation?
A) A dibucaine number of approximately 80 indicates normal pseudocholinesterase that is 80% inhibited by dibucaine, producing the standard 8 to 12 minute block; a dibucaine number of approximately 20 indicates the atypical homozygous variant most commonly responsible for prolonged block, inhibited by only 20%; and a dibucaine number of approximately 60 indicates the heterozygous state associated with moderately prolonged block of 20 to 30 minutes.
B) A dibucaine number of 20 indicates normal enzyme activity because lower inhibition by dibucaine reflects a more stable and efficient enzyme, while a dibucaine number of 80 indicates the deficient variant because higher inhibition reflects a structurally abnormal enzyme that is easily inhibited.
C) The dibucaine number reflects the total plasma concentration of pseudocholinesterase rather than enzyme structure; a value of 80 indicates high enzyme concentration and normal succinylcholine metabolism, while a value of 20 indicates low enzyme concentration from hepatic synthetic failure.
D) A dibucaine number below 50 in any patient mandates permanent avoidance of all neuromuscular blocking agents including non-depolarizing agents such as rocuronium and cisatracurium because pseudocholinesterase also metabolizes these drugs to a significant degree.
E) The dibucaine number is used to predict which patients will develop malignant hyperthermia rather than prolonged block — values below 40 identify patients with abnormal ryanodine receptor function that sensitizes them to succinylcholine-triggered calcium dysregulation.
ANSWER: A
Rationale:
This question asked you to correctly interpret the dibucaine number in the context of succinylcholine-induced prolonged block. The dibucaine number is the standard clinical test for pseudocholinesterase variants — it measures the percentage by which the local anesthetic dibucaine inhibits pseudocholinesterase activity in a plasma sample. Normal pseudocholinesterase is inhibited approximately 80% by dibucaine (dibucaine number ~80), producing the expected 8 to 12 minute succinylcholine block. The most clinically important abnormal variant is the atypical (Eu/Eu) enzyme caused by a single amino acid substitution (Asp70Gly), which is resistant to dibucaine inhibition (dibucaine number ~20) and produces block lasting several hours — so-called scoline apnea. Heterozygotes carrying one normal and one atypical gene have an intermediate dibucaine number of approximately 60 and experience moderately prolonged block of 20 to 30 minutes.
Option B: Option B is incorrect because it inverts the interpretation: a high dibucaine number indicates normal enzyme (susceptible to dibucaine inhibition), and a low number indicates the abnormal variant (resistant to inhibition).
Option C: Option C is incorrect because the dibucaine number reflects the structural quality of the enzyme — its susceptibility to dibucaine inhibition — rather than the total quantity of enzyme; plasma enzyme concentration is measured by separate activity assays.
Option D: Option D is incorrect because pseudocholinesterase does not metabolize non-depolarizing agents such as rocuronium and cisatracurium; those agents are not hydrolyzed by plasma esterases and are unaffected by pseudocholinesterase deficiency.
Option E: Option E is incorrect because the dibucaine number has no relationship to malignant hyperthermia susceptibility; MH is diagnosed by genetic testing for RYR1 mutations or by contracture testing, not by pseudocholinesterase assessment.
8. The patient with a dibucaine number of 20 remains apneic and fully paralyzed 3 hours after receiving succinylcholine. Scoline apnea secondary to homozygous pseudocholinesterase deficiency is confirmed. What is the correct management of this patient?
A) Administer neostigmine 0.07 mg/kg intravenously with glycopyrrolate to reverse the prolonged depolarizing block, using the same reversal strategy that is effective for residual non-depolarizing neuromuscular block.
B) Administer fresh frozen plasma intravenously to replenish functional pseudocholinesterase from the donor plasma, directly accelerating succinylcholine hydrolysis and shortening the duration of block.
C) Administer sugammadex 16 mg/kg intravenously — the dose used for reversal of deep neuromuscular block — because sugammadex encapsulates a broad range of neuromuscular blocking agents including succinylcholine at high plasma concentrations.
D) Provide continuous supportive care with sedation and mechanical ventilation until spontaneous neuromuscular recovery occurs; do not attempt pharmacological reversal with anticholinesterase agents, as these will worsen and prolong the block by inhibiting any residual pseudocholinesterase activity.
E) Administer calcium gluconate intravenously to stabilize the muscle membrane potential and hasten recovery from the prolonged depolarization by competitively reducing end-plate ion channel conductance.
ANSWER: D
Rationale:
This question asked you to identify the correct management of scoline apnea from pseudocholinesterase deficiency. The management is entirely supportive: maintain adequate sedation (the patient is awake and aware during scoline apnea despite being fully paralyzed — a critical concern), continue mechanical ventilation, and wait for spontaneous recovery as the remaining pseudocholinesterase activity slowly hydrolyzes the succinylcholine. Recovery may take several hours in homozygous deficiency. The critical negative rule is that anticholinesterase agents such as neostigmine must not be given — these drugs inhibit acetylcholinesterase and also inhibit any residual plasma pseudocholinesterase, the very enzyme responsible for hydrolyzing succinylcholine. Administering neostigmine would prolong the block, not reverse it.
Option A: Option A is incorrect because neostigmine is contraindicated in scoline apnea for the reason stated above; it is the reversal agent for non-depolarizing block and would be actively harmful here.
Option B: Option B is incorrect because while fresh frozen plasma theoretically contains pseudocholinesterase, this approach is not standard management; FFP carries the risks of transfusion reactions, blood-borne pathogen exposure, and transfusion-related acute lung injury, and there is no established evidence base for its use in scoline apnea.
Option C: Option C is incorrect because sugammadex encapsulates aminosteroid neuromuscular blocking agents (rocuronium and vecuronium) through a specific steroidal inclusion mechanism; it has no binding affinity for succinylcholine and cannot reverse depolarizing block of any kind.
Option E: Option E is incorrect because calcium gluconate does not reverse succinylcholine block; it is used to stabilize cardiac membrane potential in hyperkalemia but has no role in the management of prolonged depolarizing neuromuscular block.
9. Non-depolarizing neuromuscular blocking agents (NMBDs) are divided into two chemical classes — aminosteroids and benzylisoquinoliniums — each with distinct pharmacological properties that guide agent selection. A 28-year-old man with severe asthma and known allergic rhinitis requires elective surgery with neuromuscular blockade. Which of the following is a property of the aminosteroid class that makes it preferable over benzylisoquinolinium agents in this patient?
A) Aminosteroids undergo organ-independent Hofmann elimination (spontaneous chemical degradation at physiological pH and temperature), making their duration predictable regardless of the patient's hepatic or renal function and eliminating the risk of histamine release from drug metabolites.
B) Aminosteroids are fully reversible with neostigmine at any depth of block, whereas benzylisoquinoliniums can only be reversed by the cyclodextrin agent sugammadex, which is contraindicated in atopic patients with a history of drug allergies.
C) Aminosteroids do not release histamine from mast cells at clinical doses, making them appropriate for atopic patients and those with reactive airway disease, whereas benzylisoquinoliniums — particularly atracurium at higher doses — can trigger mast cell histamine release causing bronchospasm, flushing, and hypotension.
D) Aminosteroids are eliminated exclusively by the kidneys unchanged, guaranteeing a fixed and predictable duration of action that does not vary with hepatic blood flow or hepatic enzyme induction, a property particularly important in asthmatic patients on inhaled corticosteroids.
E) Aminosteroids have a direct bronchodilatory effect mediated through weak beta-2 adrenergic receptor partial agonism that is particularly beneficial in patients with reactive airway disease, counteracting any bronchoconstrictive tendency during induction.
ANSWER: C
Rationale:
This question asked you to identify the property of aminosteroid NMBDs that makes them preferable in a patient with asthma and atopy. The key distinction is histamine release: aminosteroids (rocuronium, vecuronium, pancuronium) do not release histamine from mast cells at clinical doses, making them appropriate for atopic patients and those with reactive airway disease. By contrast, benzylisoquinoliniums — particularly atracurium at doses above 0.5 mg/kg, and to a lesser extent mivacurium — can trigger mast cell histamine release in a dose- and rate-dependent fashion, producing flushing, urticaria, bronchospasm, and hypotension. Cisatracurium, a single isomer of atracurium, has minimal histamine-releasing activity at clinical doses and is an exception within the benzylisoquinolinium class.
Option A: Option A is incorrect because organ-independent Hofmann elimination is a property of the benzylisoquinolinium agents (atracurium, cisatracurium), not aminosteroids; aminosteroids are primarily eliminated via hepatic metabolism and biliary excretion.
Option B: Option B is incorrect because neostigmine reverses non-depolarizing block of both chemical classes when a sufficient train-of-four count is present; sugammadex reverses aminosteroids (not benzylisoquinoliniums), and it is not contraindicated in atopic patients.
Option D: Option D is incorrect because aminosteroids are primarily eliminated hepatically, not exclusively renally; pancuronium has significant renal elimination but rocuronium and vecuronium are predominantly hepatic.
Option E: Option E is incorrect because aminosteroids have no beta-2 adrenergic receptor activity; the distinction in this setting is entirely based on histamine release, not direct bronchodilatory effects.
10. Sugammadex is a modified gamma-cyclodextrin (a ring-shaped molecule with a hydrophobic core) that reverses neuromuscular block by a unique mechanism: it forms a tight 1:1 inclusion complex with the NMBD molecule, encapsulating it and rendering it pharmacologically inert. Which of the following statements correctly describes the selectivity of sugammadex?
A) Sugammadex reverses block from all neuromuscular blocking agents, including both aminosteroids and benzylisoquinoliniums, and at any depth of block — making it the universal reversal agent that has replaced neostigmine for all clinical indications.
B) Sugammadex selectively reverses benzylisoquinolinium agents (atracurium, cisatracurium, mivacurium) because the hydrophobic core of the cyclodextrin ring is sized to accommodate the flat isoquinoline ring structure, while the bulkier steroidal scaffold of aminosteroids does not fit.
C) Sugammadex reverses rocuronium block only and has insufficient binding affinity for vecuronium and pancuronium to be clinically useful; a separate cyclodextrin formulation with a larger ring diameter is required for those agents.
D) Sugammadex reverses aminosteroid block at moderate to deep levels only; at minimal residual block (train-of-four ratio above 0.9), neostigmine must be used because sugammadex has insufficient driving force to displace the small amount of remaining receptor-bound drug.
E) Sugammadex selectively encapsulates aminosteroid NMBDs (rocuronium with highest affinity, followed by vecuronium, and pancuronium at much lower affinity) because the steroidal scaffold fits within the hydrophobic cyclodextrin cavity; it has no activity against benzylisoquinolinium agents, which must be reversed with neostigmine when reversal is needed.
ANSWER: E
Rationale:
This question asked you to correctly characterize the selectivity of sugammadex as a reversal agent. Sugammadex works by structural inclusion — the hydrophobic cavity of the modified cyclodextrin is specifically sized and shaped to encapsulate the steroidal ring scaffold of aminosteroid NMBDs. Rocuronium fits with the highest binding affinity (the tight fit with rocuronium is the basis for its use in rapid reversal of deep rocuronium block at 16 mg/kg); vecuronium binds with somewhat lower affinity; and pancuronium binds with substantially lower affinity, making sugammadex less reliably effective for pancuronium reversal at practical doses. Critically, benzylisoquinolinium agents (atracurium, cisatracurium, mivacurium) have no steroidal structure and cannot be encapsulated by the cyclodextrin cavity — sugammadex has zero activity against this class. Benzylisoquinolinium block must be managed with neostigmine (when a sufficient train-of-four count is present) or by awaiting spontaneous recovery through Hofmann elimination or esterase hydrolysis.
Option A: Option A is incorrect because sugammadex does not reverse benzylisoquinolinium block under any circumstances.
Option B: Option B is incorrect because it inverts the selectivity: sugammadex encapsulates aminosteroids (steroidal scaffold), not benzylisoquinoliniums (isoquinoline structure).
Option C: Option C is incorrect because sugammadex has clinically meaningful affinity for both rocuronium and vecuronium; it is routinely used for vecuronium reversal, though at higher doses than for comparable depth of rocuronium block.
Option D: Option D is incorrect because sugammadex can reverse aminosteroid block at any depth — it is the only reversal agent that can reliably reverse deep block (train-of-four count of zero), which is why it is used for emergency reversal of profound rocuronium-induced block.
11. A 62-year-old man with end-stage liver disease and chronic kidney disease requiring dialysis needs neuromuscular blockade for an abdominal procedure. The anesthesiologist selects cisatracurium because of its unique elimination pathway. Which of the following correctly describes Hofmann elimination?
A) Hofmann elimination is a hepatic phase I oxidative reaction catalyzed by cytochrome P450 enzymes in which cisatracurium is converted to inactive water-soluble metabolites that are then excreted renally — a pathway that remains intact even in severe hepatic disease because only 30% of hepatic CYP capacity is required for full drug clearance.
B) Hofmann elimination is a spontaneous, non-enzymatic chemical degradation that occurs at physiological pH and body temperature — the drug breaks down on its own in the plasma and tissues without requiring any hepatic enzyme or renal excretion — making the elimination rate entirely independent of liver and kidney function.
C) Hofmann elimination describes the active transport of cisatracurium into hepatic cells by the organic anion transporting polypeptide (OATP) system, after which the drug is sequestered in bile canaliculi and excreted into the gastrointestinal tract unchanged — a pathway that bypasses renal elimination entirely.
D) Hofmann elimination refers to plasma pseudocholinesterase-mediated hydrolysis of the ester bonds in the cisatracurium molecule — the same enzyme system that hydrolyzes succinylcholine — making cisatracurium's duration prolonged in patients with pseudocholinesterase deficiency in addition to its expected Hofmann degradation.
E) Hofmann elimination is a renal tubular secretion pathway in which cisatracurium is actively transported into the proximal tubule and undergoes pH-dependent chemical degradation in the acidic tubular fluid before being excreted in the urine, explaining why its duration is prolonged only in renal failure.
ANSWER: B
Rationale:
This question asked you to define Hofmann elimination and explain why it makes cisatracurium suitable for patients with organ failure. Hofmann elimination is spontaneous, non-enzymatic chemical degradation that occurs at physiological pH (7.4) and body temperature (37°C) — no hepatic enzyme, renal function, or plasma esterase activity is required. The drug simply degrades chemically in the plasma and body fluids over time, producing laudanosine and a monoquaternary acrylate as breakdown products. Because the elimination pathway requires no organ function, cisatracurium's duration is predictable and essentially unchanged in patients with severe hepatic failure, severe renal failure, or combined organ dysfunction. This property, combined with cisatracurium's minimal histamine release, makes it the agent of choice for patients in the ICU with acute respiratory distress syndrome (ARDS), combined hepatorenal failure, or hemodynamic instability.
Option A: Option A is incorrect because Hofmann elimination is non-enzymatic and non-hepatic; it is not a cytochrome P450-mediated reaction and does not depend on hepatic enzyme capacity.
Option C: Option C is incorrect because Hofmann elimination is not a transporter-mediated hepatic uptake or biliary excretion process; the degradation is spontaneous and occurs in the bloodstream and tissues.
Option D: Option D is incorrect because Hofmann elimination is not plasma pseudocholinesterase hydrolysis; while atracurium and cisatracurium also undergo some plasma ester hydrolysis by non-specific plasma esterases, this is a separate pathway, and pseudocholinesterase deficiency does not meaningfully alter cisatracurium or atracurium duration. Mivacurium is the benzylisoquinolinium hydrolyzed by pseudocholinesterase.
Option E: Option E is incorrect because Hofmann elimination is not renal tubular secretion; it is a plasma and tissue chemical degradation event that does not depend on renal pH or tubular transport.
12. A 55-year-old woman with a known history of malignant hyperthermia susceptibility requires emergency intubation for acute respiratory failure. Succinylcholine is absolutely contraindicated. The team selects rocuronium for rapid sequence intubation and plans to have sugammadex immediately available in case intubation fails and the block must be reversed urgently. What is the correct rocuronium dose for RSI and the corresponding sugammadex dose required for immediate reversal of the resulting deep block?
A) Rocuronium 1.2 mg/kg intravenously for RSI — this high dose produces intubating conditions within 45 to 60 seconds comparable to succinylcholine, but extends the clinical duration to 60 to 90 minutes; immediate reversal of this deep block requires sugammadex 16 mg/kg intravenously.
B) Rocuronium 0.6 mg/kg intravenously for RSI — this is the standard intubating dose regardless of whether RSI conditions are required, and immediate reversal of moderate block at this dose requires sugammadex 4 mg/kg intravenously.
C) Rocuronium 0.3 mg/kg intravenously for RSI — a reduced dose is preferred when MH susceptibility is present because lower doses produce less receptor occupancy and therefore a smaller safety window for sugammadex reversal, allowing more precise titration.
D) Rocuronium 2.0 mg/kg intravenously for RSI — this supratherapeutic dose is required to overcome MH susceptibility because abnormal ryanodine receptor function reduces the sensitivity of neuromuscular receptors to non-depolarizing agents, requiring higher doses to achieve full block.
E) Rocuronium 1.2 mg/kg intravenously for RSI with neostigmine 0.07 mg/kg and glycopyrrolate for immediate reversal; sugammadex is reserved only for reversal of moderate block and cannot reverse the deep block produced by the RSI dose of rocuronium.
ANSWER: A
Rationale:
This question asked you to identify the correct rocuronium dose for RSI and the corresponding sugammadex reversal dose. At the standard intubating dose of 0.6 mg/kg, rocuronium produces intubating conditions in 60 to 90 seconds with a clinical duration of 30 to 45 minutes — reliable for elective intubation but slower than succinylcholine. For RSI where speed of onset is paramount, rocuronium at 1.2 mg/kg reduces onset to 45 to 60 seconds, producing intubating conditions comparable to succinylcholine. The trade-off is a substantially extended clinical duration of 60 to 90 minutes. The critical enabling condition for RSI use of high-dose rocuronium is the immediate availability of sugammadex 16 mg/kg — the dose required for rapid reversal of deep (profound) neuromuscular block, defined as a post-tetanic count of 1 to 2 or less. This rocuronium-sugammadex pairing eliminates the "cannot intubate, cannot oxygenate" risk that previously limited non-depolarizing agents from RSI use.
Option B: Option B is incorrect because 0.6 mg/kg at 60 to 90 second onset is too slow for emergency RSI; it is the standard elective dose, and the sugammadex dose for moderate block reversal is 4 mg/kg, not the 16 mg/kg needed for deep block.
Option C: Option C is incorrect because 0.3 mg/kg is a sub-intubating dose; MH susceptibility does not affect neuromuscular receptor sensitivity to rocuronium.
Option D: Option D is incorrect because rocuronium 2.0 mg/kg is not a standard clinical dose and MH susceptibility does not reduce nAChR sensitivity to non-depolarizing agents.
Option E: Option E is incorrect because neostigmine cannot reverse deep neuromuscular block — it requires at least a train-of-four count of 2 to be effective; moreover, sugammadex is specifically indicated for reversal of deep aminosteroid block and is the correct agent for this scenario.
13. A 58-year-old man in the ICU with septic shock and acute kidney injury has been receiving a vecuronium infusion for ventilator synchrony for the past 5 days. The infusion is discontinued, but 48 hours later the patient remains profoundly paralyzed with a train-of-four count of zero. Which of the following best explains the mechanism of this prolonged block?
A) Vecuronium has redistributed from the peripheral tissue compartment back into the central compartment over days of infusion, creating a large pharmacokinetic reservoir that continues to release active drug even after the infusion is stopped, prolonging block independently of renal function.
B) Acute kidney injury has reduced the renal excretion of the parent vecuronium molecule, which is eliminated 80% unchanged in the urine under normal conditions; accumulation of the unchanged parent drug has maintained plasma concentrations sufficient to sustain deep block.
C) Sepsis-associated critical illness polyneuropathy has caused upregulation of extrajunctional acetylcholine receptors, which are more sensitive to vecuronium than junctional receptors, amplifying the depth and duration of block beyond what would be expected from the drug concentration alone.
D) Vecuronium undergoes hepatic deacetylation to the 3-desacetyl metabolite, which retains approximately 50% of the neuromuscular blocking potency of the parent compound and is eliminated renally; in the setting of acute kidney injury, this active metabolite accumulates and can sustain profound block for days after the vecuronium infusion is discontinued.
E) Prolonged ICU paralysis with vecuronium causes downregulation of postsynaptic nAChRs at the neuromuscular junction, reducing the number of receptors that must be occupied to produce block and effectively lowering the concentration of drug required to maintain complete paralysis.
ANSWER: D
Rationale:
This question asked you to identify why vecuronium produces prolonged block in ICU patients with renal failure. Vecuronium undergoes hepatic deacetylation to three metabolites, of which the 3-desacetyl metabolite is clinically significant because it retains approximately 50% of the neuromuscular blocking potency of the parent compound. Under normal conditions this metabolite is eliminated renally. In patients with acute kidney injury or renal failure receiving prolonged vecuronium infusions in the ICU, the 3-desacetyl metabolite cannot be excreted and accumulates to concentrations sufficient to sustain deep neuromuscular block — sometimes for days beyond discontinuation of the infusion. This phenomenon of active metabolite accumulation is well-documented and is the principal reason that cisatracurium (which undergoes organ-independent Hofmann elimination and does not produce potent active metabolites) has largely replaced vecuronium for long-term ICU paralysis.
Option A: Option A is incorrect because while peripheral compartment redistribution is a real pharmacokinetic phenomenon, it does not account for days of continued profound block after infusion discontinuation; the mechanism in renal failure is specifically active metabolite accumulation.
Option B: Option B is incorrect because vecuronium is an aminosteroid primarily eliminated by hepatic metabolism and biliary excretion, not 80% renally as unchanged parent drug; that description more accurately fits pancuronium.
Option C: Option C is incorrect because while critical illness polyneuropathy can produce extrajunctional receptor upregulation, this phenomenon increases sensitivity to succinylcholine (depolarizing block), not to non-depolarizing agents — extrajunctional upregulation actually slightly reduces sensitivity to non-depolarizing agents.
Option E: Option E is incorrect because chronic receptor blockade does not cause nAChR downregulation in a clinically significant manner; the documented adaptation is upregulation of extrajunctional receptors, not downregulation of junctional receptors.
14. A 44-year-old woman with severe acute respiratory distress syndrome (ARDS) requires 48 hours of continuous neuromuscular blockade to facilitate lung-protective ventilation. She has significant hepatic dysfunction from sepsis-associated liver injury and oliguric acute kidney injury. Which neuromuscular blocking agent is most appropriate for her prolonged ICU paralysis, and why?
A) Rocuronium infusion — because it is the most widely used NDNMBD in contemporary practice and its large volume of distribution provides a pharmacokinetic buffer that prevents accumulation even in organ dysfunction when the infusion rate is titrated carefully to train-of-four monitoring.
B) Vecuronium infusion — because vecuronium has a shorter context-sensitive half-time than rocuronium during prolonged infusion and its active metabolite is renally eliminated, which provides a self-limiting mechanism that prevents accumulation above therapeutic concentrations even in renal failure.
C) Cisatracurium infusion — because its elimination occurs predominantly via Hofmann degradation, a spontaneous organ-independent chemical pathway that is unaffected by hepatic or renal dysfunction, and because it produces minimal histamine release at clinical doses, making its duration predictable and its hemodynamic profile clean in a critically ill patient.
D) Atracurium infusion — because atracurium undergoes complete Hofmann elimination with no active metabolites, making it preferable to cisatracurium in patients with combined organ dysfunction; the histamine-releasing tendency of atracurium is negligible at the low infusion doses used in the ICU setting.
E) Pancuronium infusion — because its long duration of action reduces the infusion rate required to maintain deep block, minimizing the total drug exposure over a 48-hour paralysis period and reducing the risk of active metabolite accumulation compared to intermediate-acting agents.
ANSWER: C
Rationale:
This question asked you to identify the optimal agent for prolonged ICU paralysis in a patient with combined hepatic and renal failure. Cisatracurium is the agent of choice in this clinical scenario for two convergent reasons. First, its elimination is predominantly via Hofmann degradation — spontaneous non-enzymatic chemical breakdown at physiological pH and temperature — a pathway that is entirely independent of hepatic or renal function. In a patient with both hepatic and renal dysfunction, this guarantees predictable duration without the active metabolite accumulation that complicates vecuronium use or the histamine-related hemodynamic effects that limit atracurium. Second, cisatracurium produces minimal histamine release at clinical doses, which is important in a hemodynamically unstable critically ill patient where bronchospasm or hypotension from histamine release would be poorly tolerated. The evidence base for neuromuscular blockade in ARDS (including the ACURASYS trial) was generated primarily with cisatracurium.
Option A: Option A is incorrect because rocuronium relies on hepatic metabolism and biliary excretion; in combined hepatorenal failure, its duration is prolonged and unpredictable, making it a poor choice for long-term ICU paralysis.
Option B: Option B is incorrect because vecuronium is precisely the wrong agent in renal failure due to accumulation of its active 3-desacetyl metabolite, which is renally eliminated; this is not a self-limiting mechanism but a mechanism for dangerous prolonged block.
Option D: Option D is incorrect because atracurium, while also undergoing Hofmann elimination, produces greater amounts of laudanosine per milligram administered than cisatracurium and has more significant histamine-releasing activity at the doses needed for sustained block; cisatracurium is preferred over atracurium in the ICU for both reasons.
Option E: Option E is incorrect because pancuronium relies predominantly on renal elimination and would accumulate markedly in a patient with oliguric acute kidney injury, producing prolonged and uncontrollable block.
15. A 70-year-old man with severe coronary artery disease, a baseline heart rate of 88 beats per minute, and stage 3 chronic kidney disease (estimated GFR 32 mL/min) requires neuromuscular blockade for a prolonged abdominal procedure. The anesthesiologist considers pancuronium as an option but decides against it. Which of the following correctly identifies the two properties of pancuronium that make it inappropriate for this patient?
A) Pancuronium releases histamine in a dose-dependent manner and undergoes Hofmann elimination, making it inappropriate in this patient because histamine-induced bronchospasm would worsen his cardiac hemodynamics and Hofmann elimination is impaired in renal failure, prolonging the block unpredictably.
B) Pancuronium is a short-acting agent with a clinical duration of only 10 to 15 minutes that requires frequent re-dosing, and it undergoes extensive hepatic first-pass metabolism that is significantly reduced in elderly patients, causing accumulation and prolonged block with repeated administration.
C) Pancuronium is not reversible by sugammadex at any practically achievable dose and also produces significant direct myocardial depression, making it inappropriate in a patient with compromised coronary reserve and necessitating backup defibrillation capability throughout its use.
D) Pancuronium undergoes plasma pseudocholinesterase hydrolysis, so any degree of renal impairment reduces pseudocholinesterase production by the kidney and prolongs pancuronium duration; additionally, pancuronium directly inhibits sinoatrial node automaticity, causing bradycardia rather than tachycardia.
E) Pancuronium is eliminated approximately 80% unchanged by the kidneys, making its duration markedly prolonged in renal impairment; and it blocks cardiac muscarinic receptors while inhibiting neuronal catecholamine reuptake, producing tachycardia and increased blood pressure that are poorly tolerated in a patient with underlying coronary artery disease.
ANSWER: E
Rationale:
This question asked you to identify the two properties of pancuronium that make it a poor choice in a patient with renal impairment and coronary artery disease. First, pancuronium is eliminated approximately 80% unchanged by the kidneys — making it markedly sensitive to renal impairment; in a patient with an eGFR of 32 mL/min, pancuronium duration will be substantially prolonged and unpredictable, increasing the risk of residual block at the end of surgery. Second, pancuronium blocks cardiac muscarinic receptors (vagolytic effect), producing tachycardia, and also inhibits neuronal uptake of catecholamines, modestly increasing heart rate and blood pressure. In a patient with significant coronary artery disease already at a heart rate of 88 bpm, pancuronium-induced tachycardia increases myocardial oxygen demand and reduces diastolic filling time, increasing the risk of perioperative myocardial ischemia.
Option A: Option A is incorrect because pancuronium does not release histamine (it is an aminosteroid) and does not undergo Hofmann elimination (which is a benzylisoquinolinium property).
Option B: Option B is incorrect because pancuronium is a long-acting agent with a clinical duration of 60 to 90 minutes, not a short-acting agent; it undergoes hepatic and renal elimination, not extensive hepatic first-pass metabolism.
Option C: Option C is incorrect because while pancuronium has low sugammadex binding affinity at clinical doses, it does not cause myocardial depression — its cardiovascular effect is stimulatory (tachycardia and mild hypertension).
Option D: Option D is incorrect because pancuronium is not hydrolyzed by plasma pseudocholinesterase; pseudocholinesterase is not produced by the kidneys; and pancuronium causes tachycardia, not bradycardia, through its muscarinic blocking action.
16. A patient receives atracurium 0.6 mg/kg as a rapid intravenous bolus for elective intubation. Within 2 minutes, the anesthesiologist observes diffuse facial and chest flushing, urticaria along the IV site, a blood pressure drop from 128/76 to 94/58 mmHg, and audible expiratory wheeze. Which of the following best explains this adverse reaction and the strategy to minimize it?
A) This reaction represents a true type I IgE-mediated anaphylactic response to the atracurium benzylisoquinolinium scaffold; the reaction is unpredictable, dose-independent, and can only be prevented by prior skin-prick testing for atracurium hypersensitivity before any future use.
B) Atracurium releases histamine from mast cells in a dose- and rate-dependent fashion at doses above approximately 0.5 mg/kg; the flush, urticaria, bronchospasm, and hypotension observed are direct consequences of this histamine release, and the reaction can be substantially attenuated by administering the drug slowly over 30 to 60 seconds and keeping the dose below the threshold level.
C) Atracurium activates the complement cascade through the alternative pathway, causing anaphylactoid degranulation of mast cells and basophils in a complement-mediated reaction that is dose-independent and not attenuated by slowing the rate of drug administration.
D) The reaction reflects direct myocardial depression caused by atracurium at doses above 0.5 mg/kg, as the drug non-selectively blocks calcium channels in myocardial cells at supratherapeutic concentrations, reducing cardiac output and causing reflex bronchospasm through vagal stimulation.
E) Atracurium competitively blocks beta-2 adrenergic receptors in bronchial smooth muscle at higher doses, causing bronchoconstriction and the associated hemodynamic changes; pretreatment with an inhaled beta-2 agonist prevents this reaction by occupying the receptor before atracurium is administered.
ANSWER: B
Rationale:
This question asked you to identify the mechanism and mitigation strategy for the adverse hemodynamic and cutaneous reaction caused by atracurium. Atracurium releases histamine from mast cells through a direct, non-immunological mechanism that is both dose-dependent and rate-dependent. At doses at or below 0.5 mg/kg, histamine release is minimal and usually clinically insignificant. At doses above 0.5 mg/kg — and particularly when administered as a rapid bolus — the reaction can be pronounced, producing the classic triad of flushing, urticaria, and hypotension, with bronchospasm in susceptible individuals. Administering atracurium slowly over 30 to 60 seconds substantially attenuates but does not eliminate the histamine-releasing tendency. Cisatracurium, a single purified isomer of atracurium approximately three times more potent, has markedly reduced histamine-releasing activity at clinical doses and is the preferred choice when histamine release is a concern.
Option A: Option A is incorrect because atracurium histamine release is a direct non-immunological (non-IgE-mediated) pharmacological effect, not a type I anaphylactic reaction; it is predictably dose- and rate-dependent and does not require prior sensitization.
Option C: Option C is incorrect because atracurium histamine release is not complement-mediated; it is a direct effect on mast cells that is attenuated by slower administration.
Option D: Option D is incorrect because atracurium does not block myocardial calcium channels at clinical doses; the hypotension is histamine-mediated vasodilation, not myocardial depression.
Option E: Option E is incorrect because atracurium does not block beta-2 adrenergic receptors; the bronchospasm is caused by histamine acting on H1 receptors in bronchial smooth muscle, not by beta-adrenergic blockade.
17. During Hofmann elimination of atracurium at physiological pH and temperature, the molecule degrades spontaneously to produce a tertiary amine compound called laudanosine. What is the clinical significance of laudanosine accumulation, and why does it warrant monitoring in certain patients?
A) Laudanosine is a tertiary amine (meaning it carries no permanent positive charge) that can cross the blood-brain barrier — the protective membrane separating the bloodstream from the central nervous system — and at high concentrations has been shown to cause CNS excitation and seizures in animal models; while clinically significant neurotoxicity has not been observed at normal therapeutic doses in humans, prolonged high-dose atracurium infusions in ICU patients can lead to laudanosine accumulation that warrants consideration, which is one reason cisatracurium is preferred for long-term ICU use.
B) Laudanosine is a potent non-depolarizing neuromuscular blocking agent — more potent than the parent atracurium molecule — that accumulates in the plasma and peripherally innervated muscle beds during prolonged atracurium infusion, extending the duration of neuromuscular block well beyond the expected Hofmann degradation time.
C) Laudanosine is a competitive antagonist at cardiac beta-1 adrenergic receptors that accumulates during prolonged atracurium infusion and produces clinically significant bradycardia and negative inotropy, particularly in elderly patients and those with pre-existing conduction system disease.
D) Laudanosine directly inhibits hepatic cytochrome P450 enzymes, reducing the metabolism of co-administered drugs including opioid analgesics and benzodiazepines, leading to unintended drug accumulation and prolonged sedation in ICU patients receiving concurrent atracurium infusions.
E) Laudanosine is an active muscarinic agonist that produces parasympathomimetic effects including bradycardia, bronchospasm, and excessive secretions during prolonged atracurium use; these effects are managed with concurrent anticholinergic prophylaxis using glycopyrrolate.
ANSWER: A
Rationale:
This question asked you to identify the clinical significance of laudanosine, the principal Hofmann degradation product of atracurium. Laudanosine is a tertiary amine — unlike the quaternary ammonium parent molecule, it lacks a permanent positive charge. This structural difference is pharmacologically critical: quaternary ammonium compounds are highly polar, do not cross lipid membranes well, and are excluded from the central nervous system by the blood-brain barrier. Tertiary amines are more lipophilic and cross the blood-brain barrier readily. In animal models, laudanosine at high concentrations produces dose-dependent CNS excitation and seizures. In humans receiving atracurium at clinical doses for routine anesthesia, laudanosine accumulation does not reach concentrations associated with detectable CNS effects. However, in ICU patients receiving prolonged high-dose atracurium infusions — particularly in the setting of renal failure, which impairs laudanosine clearance — accumulation may be clinically relevant. Cisatracurium generates substantially less laudanosine per milligram administered than atracurium (because of its greater potency and therefore lower required dose) and is the preferred agent for prolonged ICU infusion.
Option B: Option B is incorrect because laudanosine has no neuromuscular blocking activity; it is a CNS-active compound, not a peripheral nAChR antagonist.
Option C: Option C is incorrect because laudanosine does not block cardiac beta-1 receptors; its activity is CNS excitatory, not cardiac negative chronotropic.
Option D: Option D is incorrect because laudanosine does not inhibit hepatic CYP enzymes at clinically relevant concentrations; CYP inhibition is not a documented concern with laudanosine accumulation.
Option E: Option E is incorrect because laudanosine is not a muscarinic agonist; it produces CNS excitation, not parasympathomimetic peripheral cholinergic effects.
18. A patient with a known history of prolonged succinylcholine block (later confirmed to be due to heterozygous pseudocholinesterase deficiency) requires a short elective procedure. The anesthesiologist considers mivacurium as an alternative short-acting agent. Which of the following correctly identifies the pharmacokinetic property that makes mivacurium an inappropriate choice in this patient, and why?
A) Mivacurium undergoes Hofmann elimination at the same rate as atracurium, and pseudocholinesterase deficiency slows the Hofmann pathway by reducing an essential cofactor, prolonging mivacurium duration by the same degree as it prolongs succinylcholine duration.
B) Mivacurium is eliminated exclusively by renal tubular secretion, and pseudocholinesterase deficiency is commonly associated with reduced renal tubular transport capacity because both depend on the same hepatic synthetic enzyme systems for their normal function.
C) Mivacurium is an aminosteroid agent requiring sugammadex for reversal, and pseudocholinesterase deficiency reduces sugammadex binding affinity for the mivacurium-steroidal scaffold, making reversal unreliable in this patient population.
D) Mivacurium is hydrolyzed by plasma pseudocholinesterase — the same enzyme responsible for succinylcholine metabolism — so patients with pseudocholinesterase deficiency who experience prolonged succinylcholine block will also experience markedly prolonged mivacurium block, making mivacurium an unsafe choice in a patient with confirmed pseudocholinesterase deficiency.
E) Mivacurium competes with succinylcholine for plasma pseudocholinesterase binding sites; in a patient with prior succinylcholine exposure, residual succinylcholine fragments occupy the enzyme and slow mivacurium hydrolysis, but this interaction is only significant within 24 hours of the prior succinylcholine administration.
ANSWER: D
Rationale:
This question asked you to identify why mivacurium is contraindicated in a patient with pseudocholinesterase deficiency. Mivacurium is a short-acting benzylisoquinolinium NMBD whose primary route of elimination is hydrolysis by plasma pseudocholinesterase (butyrylcholinesterase) — the same enzyme responsible for succinylcholine metabolism. This shared enzymatic dependency means that a patient who has pseudocholinesterase deficiency sufficient to prolong succinylcholine from the expected 8 to 12 minutes to a substantially longer duration will experience proportionally prolonged mivacurium block as well. In a patient with confirmed heterozygous pseudocholinesterase deficiency (dibucaine number ~60), mivacurium block that would normally last 12 to 20 minutes may extend significantly. In a homozygous deficient patient, mivacurium could produce hours of block. This is a clinically critical interaction — selecting mivacurium as a "safe short-acting alternative" in a known pseudocholinesterase-deficient patient would replicate the same problem that occurred with succinylcholine.
Option A: Option A is incorrect because mivacurium is not eliminated by Hofmann elimination; its primary route is pseudocholinesterase hydrolysis, and pseudocholinesterase deficiency does not affect Hofmann degradation.
Option B: Option B is incorrect because mivacurium is not renally secreted; it is plasma-hydrolyzed, and there is no association between pseudocholinesterase deficiency and renal tubular transport capacity.
Option C: Option C is incorrect because mivacurium is a benzylisoquinolinium, not an aminosteroid; it cannot be reversed by sugammadex regardless of pseudocholinesterase status, and sugammadex binding is not affected by pseudocholinesterase function.
Option E: Option E is incorrect because there is no competitive interaction between residual succinylcholine fragments and mivacurium at a clinically meaningful level; the concern is enzyme deficiency reducing mivacurium hydrolysis, not enzyme competition from prior drug exposure.
19. For each of the following clinical scenarios, a specific neuromuscular blocking agent property is the decisive selection criterion. A patient with alcoholic cirrhosis and hepatorenal syndrome requires neuromuscular blockade for an urgent procedure. Which agent and which property make it the rational choice?
A) Rocuronium — because its high lipophilicity results in rapid redistribution from the neuromuscular junction into peripheral tissue compartments in patients with ascites, effectively shortening the duration of block toward normal despite impaired hepatic clearance.
B) Vecuronium — because its 3-desacetyl metabolite is eliminated via bile rather than urine in patients with hepatic disease, and the hepatorenal syndrome causes selective renal impairment without affecting biliary excretion of the active metabolite.
C) Cisatracurium — because its elimination by Hofmann degradation is entirely independent of hepatic metabolism and renal excretion, making its pharmacokinetics predictable in a patient with combined hepatic and renal failure where aminosteroid and other organ-dependent agents would accumulate unpredictably.
D) Atracurium — because hepatorenal syndrome stimulates compensatory upregulation of plasma esterase activity that accelerates the non-Hofmann ester hydrolysis pathway of atracurium, normalizing its duration compared to a patient with isolated organ dysfunction.
E) Pancuronium — because hepatic failure reduces the rate of first-pass biliary excretion of pancuronium, which paradoxically shortens its duration of action by increasing systemic redistribution and reducing the plasma concentration driving receptor occupancy at the neuromuscular junction.
ANSWER: C
Rationale:
This question asked you to identify the optimal NMBD in a patient with combined hepatic and renal failure — the specific clinical scenario where organ-independent elimination is the decisive property. Cisatracurium's elimination via Hofmann degradation is spontaneous chemical breakdown at physiological pH and temperature that requires no hepatic enzyme activity and no renal excretion. In a patient with both hepatic failure (cirrhosis) and renal failure (hepatorenal syndrome), every aminosteroid agent will have prolonged and unpredictable duration: rocuronium and vecuronium depend on hepatic metabolism and biliary excretion; pancuronium depends predominantly on renal excretion. Atracurium undergoes Hofmann elimination but also produces more laudanosine and more histamine than cisatracurium. Cisatracurium provides predictable intermediate duration, minimal histamine release, and no organ-dependent metabolite accumulation — making it the unambiguous choice in combined organ failure.
Option A: Option A is incorrect because redistribution does not normalize rocuronium duration in hepatic failure; hepatic clearance impairment prolongs rocuronium duration substantially, and ascites expands the volume of distribution in a way that further complicates duration prediction rather than normalizing it.
Option B: Option B is incorrect because vecuronium's active 3-desacetyl metabolite is renally eliminated, and hepatorenal syndrome — by definition — causes renal failure, meaning the metabolite will accumulate; the premise of selective preservation of biliary excretion in hepatorenal syndrome is incorrect.
Option D: Option D is incorrect because hepatorenal syndrome does not upregulate plasma esterase activity; no compensatory increase in non-Hofmann ester hydrolysis occurs in this condition.
Option E: Option E is incorrect because pancuronium is approximately 80% renally eliminated unchanged; hepatic failure does not shorten its duration, and hepatorenal syndrome — causing renal failure — would markedly prolong pancuronium block.
20. Rocuronium is the most widely used non-depolarizing neuromuscular blocking agent in contemporary anesthesia practice. A 40-year-old healthy man with normal organ function requires elective intubation for a laparoscopic cholecystectomy expected to last 45 minutes. The anesthesiologist selects rocuronium at the standard intubating dose. Which of the following correctly describes the onset time and clinical duration of rocuronium at 0.6 mg/kg?
A) Onset within 30 to 40 seconds at the larynx with a clinical duration of 15 to 20 minutes — a profile identical to succinylcholine at standard doses, making rocuronium interchangeable with succinylcholine for all clinical indications including RSI.
B) Onset within 45 to 60 seconds at the larynx with a clinical duration of 60 to 90 minutes — a profile that matches the RSI dose of 1.2 mg/kg and is the basis for rocuronium's role as the primary agent for procedures lasting more than one hour.
C) Onset within 3 to 5 minutes with a clinical duration of 20 to 25 minutes — an onset profile similar to other intermediate-acting agents at standard doses, reflecting the time required for sufficient receptor occupancy at the slower-onset standard dose.
D) Onset within 60 to 90 seconds with a clinical duration of 25 to 35 minutes — a profile that is adequate for most elective procedures but requires neostigmine reversal at the end of every case due to its inability to recover spontaneously within the surgical timeframe.
E) Onset within 60 to 90 seconds at the larynx with a clinical duration of 30 to 45 minutes — making it appropriate for the planned 45-minute procedure at this dose, with recovery options including either neostigmine (when train-of-four recovery is adequate) or sugammadex (at any depth of block).
ANSWER: E
Rationale:
This question asked you to recall the standard onset and duration profile of rocuronium at 0.6 mg/kg. At the standard intubating dose of 0.6 mg/kg, rocuronium produces intubating conditions at the larynx within 60 to 90 seconds with a clinical duration of 30 to 45 minutes at the adductor pollicis — well-matched to the 45-minute procedure planned. This is slower than succinylcholine (45 to 60 seconds) and slower than rocuronium at the RSI dose of 1.2 mg/kg, but adequate for elective intubation where a full-stomach emergency is not the driving concern. Recovery can be facilitated with either neostigmine (when a train-of-four count of at least 2 is present) or sugammadex (at any depth of block), providing flexible reversal options.
Option A: Option A is incorrect because 0.6 mg/kg rocuronium onset is 60 to 90 seconds — slower than succinylcholine's 45 to 60 seconds — and the 15 to 20 minute duration stated is too short; the actual clinical duration at 0.6 mg/kg is 30 to 45 minutes.
Option B: Option B is incorrect because the 60 to 90 minute clinical duration described matches the RSI dose of 1.2 mg/kg, not the 0.6 mg/kg standard dose.
Option C: Option C is incorrect because rocuronium at 0.6 mg/kg achieves onset within 60 to 90 seconds — not 3 to 5 minutes; 3 to 5 minutes would be closer to the onset of older longer-acting agents at lower doses.
Option D: Option D is incorrect because the clinical duration of 25 to 35 minutes is slightly low for 0.6 mg/kg rocuronium (30 to 45 minutes is more accurate), and the claim that neostigmine is required at the end of every case is incorrect — spontaneous partial recovery combined with sugammadex or adequate train-of-four count for neostigmine is always a viable route.
21. A 35-year-old man presents to the emergency department after a penetrating injury to the right eye (open globe injury) and requires urgent surgical repair. He last ate 3 hours ago, creating a full-stomach aspiration risk. The emergency physician asks whether succinylcholine can be used for rapid sequence intubation given the ocular injury. Which of the following correctly characterizes the effect of succinylcholine on intraocular pressure (IOP) and its clinical implication in this patient?
A) Succinylcholine reliably reduces intraocular pressure by 10 to 15 mmHg through direct relaxation of extraocular muscles and ciliary body smooth muscle; this property makes it the preferred RSI agent in open globe injuries because the pressure reduction protects against vitreous extrusion during laryngoscopy.
B) Succinylcholine causes a transient increase in intraocular pressure — resulting from sustained contraction of extraocular muscles producing external compression on the globe — and in the setting of an open globe injury this IOP rise creates a theoretical risk of vitreous extrusion; however, the clinical evidence for this risk is not definitive, and the risk of aspiration in a full-stomach patient must be weighed against the theoretical ocular risk in the overall management decision.
C) Succinylcholine has no clinically meaningful effect on intraocular pressure because its depolarizing block simultaneously relaxes and contracts all periocular muscles in an exactly balanced fashion, producing net zero change in external ocular compression.
D) Succinylcholine markedly increases intraocular pressure through a mechanism identical to its hyperkalemia risk — upregulation of extrajunctional nAChRs in the extraocular muscles after any penetrating eye injury causes an exaggerated succinylcholine-induced contraction that raises IOP by 30 to 40 mmHg in all patients with prior ocular trauma.
E) The intraocular pressure effect of succinylcholine is clinically irrelevant in open globe management because the lower esophageal sphincter-tightening effect of succinylcholine prevents any aspiration event during the period of elevated IOP, effectively eliminating the need to choose between the two risks.
ANSWER: B
Rationale:
This question asked you to characterize the IOP effect of succinylcholine and its significance in open globe injury. Succinylcholine produces a transient increase in intraocular pressure, primarily through sustained contraction of the extraocular muscles that compress the globe externally; this IOP rise typically peaks at 1 to 4 minutes after injection and resolves as the block deepens and muscles relax. In the setting of an open globe injury — where the integrity of the globe is already compromised — this pressure increase raises a theoretical concern about extrusion of intraocular contents (vitreous, lens, iris) through the wound. However, the clinical evidence that succinylcholine-induced IOP rise actually causes vitreous extrusion in humans is not definitive, and the absolute magnitude of the IOP increase at standard doses is generally modest. In a full-stomach patient, the aspiration risk is concrete and potentially immediately life-threatening, while the IOP risk remains theoretical. Many anesthesiologists accept succinylcholine for open globe RSI with the understanding that meticulous induction technique minimizes straining and coughing that would raise IOP far more than the drug alone. Rocuronium 1.2 mg/kg with sugammadex availability is the alternative for those who prefer to avoid succinylcholine entirely.
Option A: Option A is incorrect because succinylcholine increases IOP rather than decreasing it; it does not relax extraocular muscles — it produces a depolarizing contraction that compresses the globe.
Option C: Option C is incorrect because the extraocular muscle contraction produces a net IOP increase, not a balanced zero effect.
Option D: Option D is incorrect because the mechanism of IOP increase in open globe injury is not extrajunctional nAChR upregulation — that mechanism drives hyperkalemia in denervated and burned tissue; the extraocular muscles in a penetrating eye injury are not denervated in the manner required for extrajunctional upregulation, and a 30 to 40 mmHg rise is an exaggeration.
Option E: Option E is incorrect because the lower esophageal sphincter effect does not prevent aspiration risk and has no bearing on IOP management; the two risks cannot be eliminated by one mechanism.
22. Which of the following neuromuscular blocking agents should be specifically avoided in a patient with known coronary artery disease and a resting heart rate of 92 beats per minute, and what is the pharmacological basis for this recommendation?
A) Pancuronium — because it blocks cardiac muscarinic receptors (producing a vagolytic tachycardia) and also inhibits the neuronal reuptake of norepinephrine at sympathetic terminals (raising circulating catecholamine levels), together increasing heart rate and blood pressure; in a patient with coronary artery disease and already elevated heart rate, this combination increases myocardial oxygen demand and reduces coronary diastolic filling time, raising the risk of perioperative myocardial ischemia.
B) Cisatracurium — because its Hofmann degradation product laudanosine has potent cardiac sympathomimetic activity that raises heart rate by 20 to 30 beats per minute in patients with pre-existing sympathetic tone elevation, making it unsuitable in tachycardic coronary artery disease patients.
C) Rocuronium — because its high lipophilicity allows it to partition into myocardial tissue and block calcium channels in coronary artery smooth muscle, producing coronary vasospasm and ST-segment elevation in patients with pre-existing atherosclerotic disease.
D) Succinylcholine — because its depolarizing mechanism activates cardiac nicotinic receptors in the sinoatrial node, producing dose-dependent tachycardia proportional to the plasma succinylcholine concentration and worsening myocardial oxygen demand in susceptible patients.
E) Vecuronium — because its 3-desacetyl metabolite has strong beta-1 adrenergic receptor agonist activity that accumulates during prolonged use and produces sustained tachycardia independently of the parent compound's neuromuscular blocking action.
ANSWER: A
Rationale:
This question asked you to identify which NMBD is specifically contraindicated in coronary artery disease with tachycardia and to explain the pharmacological basis. Pancuronium is the agent that must be avoided in this setting. Its cardiovascular effects arise from two distinct mechanisms: first, it blocks cardiac muscarinic (M2) receptors, eliminating parasympathetic slowing of heart rate and producing a vagolytic tachycardia; second, it inhibits the neuronal reuptake of norepinephrine at sympathetic nerve terminals, raising effective catecholamine concentrations at adrenergic receptors and further increasing heart rate and blood pressure. In a healthy patient these effects were historically viewed as hemodynamically favorable (counteracting opioid-induced bradycardia in high-dose narcotic cardiac anesthesia), but in a patient with underlying coronary artery disease and a baseline heart rate already at 92 bpm, the additional heart rate increase raises myocardial oxygen demand, shortens diastolic filling time, and reduces subendocardial perfusion — collectively increasing the risk of perioperative myocardial ischemia. All other aminosteroids (rocuronium, vecuronium) and benzylisoquinoliniums at clinical doses have minimal direct cardiovascular effects and are appropriate alternatives.
Option B: Option B is incorrect because laudanosine is a CNS excitant at high concentrations in animal models and does not have potent cardiac sympathomimetic activity; it does not produce clinically significant tachycardia.
Option C: Option C is incorrect because rocuronium does not block coronary calcium channels or cause coronary vasospasm; it has minimal cardiovascular effects at clinical doses.
Option D: Option D is incorrect because succinylcholine does not activate cardiac nicotinic receptors to produce dose-dependent tachycardia; its cardiac effect — bradycardia from muscarinic stimulation — is the opposite of tachycardia and is most pronounced in children and with repeated doses.
Option E: Option E is incorrect because vecuronium's 3-desacetyl metabolite does not have beta-1 adrenergic agonist activity; vecuronium is specifically notable for its minimal cardiovascular effects compared to pancuronium, which is why it replaced pancuronium in cardiac anesthesia.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.